tetano
Editor, Senior Moderator
Clin Rheumatol. 2013 Nov 28. [Epub ahead of print]
Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.
Sengler C, Niewerth M, Kallinich T, Nimtz-Talaska A, Haller M, Huppertz HI, Minden K.
Source
Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charit?platz 1, 10117, Berlin, Germany, sengler@drfz.de.
Abstract
The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.
PMID:
24288046
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24288046
Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.
Sengler C, Niewerth M, Kallinich T, Nimtz-Talaska A, Haller M, Huppertz HI, Minden K.
Source
Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charit?platz 1, 10117, Berlin, Germany, sengler@drfz.de.
Abstract
The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.
PMID:
24288046
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24288046